Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Boehringer Ingelheim

Last Updated: October 6, 2022

Details for Patent: 8,791,140

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,791,140 protect, and when does it expire?

Patent 8,791,140 protects INLYTA and is included in one NDA.

This patent has thirty patent family members in twenty-two countries.

Summary for Patent: 8,791,140
Title:Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
Abstract: The present invention relates to crystalline polymorphic and amorphous form of 6-[2-(methylcarbamoyl)phenyl sulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one polymorphic form and to the therapeutic or prophylactic use of such polymorphic forms and compositions.
Inventor(s): Campeta; Anthony Michael (Ledyard, CT), Chekal; Brian Patrick (Niantic, CT), Singer; Robert Alan (Niantic, CT)
Assignee: Pfizer Inc. (New York, NY)
Application Number:12/594,575
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,791,140
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 8,791,140

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-001 Jan 27, 2012 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-002 Jan 27, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,791,140

PCT Information
PCT FiledMarch 25, 2008PCT Application Number:PCT/IB2008/000792
PCT Publication Date:October 16, 2008PCT Publication Number: WO2008/122858

International Family Members for US Patent 8,791,140

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 065931 See Plans and Pricing
Australia 2008236444 See Plans and Pricing
Brazil PI0809471 See Plans and Pricing
Canada 2682859 See Plans and Pricing
China 101679356 See Plans and Pricing
China 103626739 See Plans and Pricing
Cyprus 1119119 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.